AP945A - Encapsulated solution dosage forms of sertraline. - Google Patents

Encapsulated solution dosage forms of sertraline. Download PDF

Info

Publication number: AP945A
Authority: AP; ARIPO
Prior art keywords: sertraline; dosage form; mga; oil; vehicle
Prior art date: 1997-07-01

Application number

APAP/P/1998/001279A

Other languages

English (en)

Other versions

AP9801279A0 (en

Inventor

William John Curatolo

Ravi Mysore Shanker

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-01

Filing date

1998-06-25

Publication date

2001-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP945(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

1998-06-30 Publication of AP9801279A0 publication Critical patent/AP9801279A0/xx

2001-02-28 Application granted granted Critical

2001-02-28 Publication of AP945A publication Critical patent/AP945A/en

Links

239000002552 dosage form Substances 0.000 title claims abstract description 65
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 title claims description 228
229960002073 sertraline Drugs 0.000 title claims description 215
238000001556 precipitation Methods 0.000 claims abstract description 27
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 20
230000007423 decrease Effects 0.000 claims abstract description 15
239000003981 vehicle Substances 0.000 claims description 84
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 21
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 21
229940068968 polysorbate 80 Drugs 0.000 claims description 21
229920000053 polysorbate 80 Polymers 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
235000019485 Safflower oil Nutrition 0.000 claims description 15
239000003813 safflower oil Substances 0.000 claims description 15
235000005713 safflower oil Nutrition 0.000 claims description 15
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 11
239000003921 oil Substances 0.000 claims description 10
235000019198 oils Nutrition 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 9
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 8
239000004094 surface-active agent Substances 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
239000004006 olive oil Substances 0.000 claims description 7
235000008390 olive oil Nutrition 0.000 claims description 7
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 6
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 6
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
239000005642 Oleic acid Substances 0.000 claims description 6
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000003995 emulsifying agent Substances 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
150000004665 fatty acids Chemical class 0.000 claims description 6
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 6
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
239000008158 vegetable oil Substances 0.000 claims description 6
239000008136 water-miscible vehicle Substances 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 3
235000011187 glycerol Nutrition 0.000 claims description 3
239000008159 sesame oil Substances 0.000 claims description 3
235000011803 sesame oil Nutrition 0.000 claims description 3
CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 claims description 2
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 2
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
239000005639 Lauric acid Substances 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
239000004359 castor oil Substances 0.000 claims description 2
235000019438 castor oil Nutrition 0.000 claims description 2
239000003240 coconut oil Substances 0.000 claims description 2
235000019864 coconut oil Nutrition 0.000 claims description 2
235000012343 cottonseed oil Nutrition 0.000 claims description 2
239000002385 cottonseed oil Substances 0.000 claims description 2
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
229960002446 octanoic acid Drugs 0.000 claims description 2
239000003549 soybean oil Substances 0.000 claims description 2
235000012424 soybean oil Nutrition 0.000 claims description 2
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
235000019483 Peanut oil Nutrition 0.000 claims 1
239000002202 Polyethylene glycol Substances 0.000 claims 1
235000020778 linoleic acid Nutrition 0.000 claims 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
239000000312 peanut oil Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 12
210000001035 gastrointestinal tract Anatomy 0.000 abstract description 9
239000000243 solution Substances 0.000 description 81
239000002585 base Substances 0.000 description 24
239000003826 tablet Substances 0.000 description 21
GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 20
229940079593 drug Drugs 0.000 description 19
239000003814 drug Substances 0.000 description 19
239000002904 solvent Substances 0.000 description 18
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000000499 gel Substances 0.000 description 16
239000008273 gelatin Substances 0.000 description 16
229920000159 gelatin Polymers 0.000 description 16
239000012530 fluid Substances 0.000 description 14
239000007903 gelatin capsule Substances 0.000 description 14
238000001802 infusion Methods 0.000 description 13
229940068918 polyethylene glycol 400 Drugs 0.000 description 13
108010010803 Gelatin Proteins 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
239000002775 capsule Substances 0.000 description 12
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
239000012458 free base Substances 0.000 description 12
230000002496 gastric effect Effects 0.000 description 12
235000019322 gelatine Nutrition 0.000 description 12
235000011852 gelatine desserts Nutrition 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
150000003626 triacylglycerols Chemical class 0.000 description 12
229940068196 placebo Drugs 0.000 description 11
239000000902 placebo Substances 0.000 description 11
210000002784 stomach Anatomy 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000010521 absorption reaction Methods 0.000 description 10
239000012738 dissolution medium Substances 0.000 description 10
239000012729 immediate-release (IR) formulation Substances 0.000 description 10
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 9
210000001198 duodenum Anatomy 0.000 description 8
230000000968 intestinal effect Effects 0.000 description 8
239000012071 phase Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 7
238000009472 formulation Methods 0.000 description 7
238000004128 high performance liquid chromatography Methods 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000693 micelle Substances 0.000 description 7
210000000813 small intestine Anatomy 0.000 description 7
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 5
238000005538 encapsulation Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
229960003660 sertraline hydrochloride Drugs 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
229940009098 aspartate Drugs 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
150000003893 lactate salts Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
229940020965 zoloft Drugs 0.000 description 4
OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 3
244000020518 Carthamus tinctorius Species 0.000 description 3
235000003255 Carthamus tinctorius Nutrition 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000036760 body temperature Effects 0.000 description 3
GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
230000002183 duodenal effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000004530 micro-emulsion Substances 0.000 description 3
239000007935 oral tablet Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229940068917 polyethylene glycols Drugs 0.000 description 3
206010036596 premature ejaculation Diseases 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
235000013772 propylene glycol Nutrition 0.000 description 3
238000011287 therapeutic dose Methods 0.000 description 3
210000003384 transverse colon Anatomy 0.000 description 3
239000003643 water by type Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
240000007817 Olea europaea Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000207961 Sesamum Species 0.000 description 2
235000003434 Sesamum indicum Nutrition 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
229940096978 oral tablet Drugs 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
230000004044 response Effects 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
239000008279 sol Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102100039845 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Human genes 0.000 description 1
101710112841 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Proteins 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
206010067171 Regurgitation Diseases 0.000 description 1
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
229940125709 anorectic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000003965 capillary gas chromatography Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000005352 clarification Methods 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001211 electron capture detection Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940074046 glyceryl laurate Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003870 intestinal permeability Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940037959 monooctanoin Drugs 0.000 description 1
229940074096 monoolein Drugs 0.000 description 1
230000008450 motivation Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
238000005192 partition Methods 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
-1 propylene glycol ester Chemical class 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
229940117972 triolein Drugs 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

APAP/P/1998/001279A 1997-07-01 1998-06-25 Encapsulated solution dosage forms of sertraline. AP945A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5140197P	1997-07-01	1997-07-01

Publications (2)

Publication Number	Publication Date
AP9801279A0 AP9801279A0 (en)	1998-06-30
AP945A true AP945A (en)	2001-02-28

Family

ID=21971076

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1998/001279A AP945A (en)	1997-07-01	1998-06-25	Encapsulated solution dosage forms of sertraline.

Country Status (40)

Country	Link
EP (1)	EP0980241B1 (is)
JP (1)	JP3585245B2 (is)
KR (1)	KR100371730B1 (is)
CN (1)	CN1261792A (is)
AP (1)	AP945A (is)
AR (1)	AR015916A1 (is)
AT (1)	ATE256457T1 (is)
AU (1)	AU724635B2 (is)
BG (1)	BG103917A (is)
BR (1)	BR9809712A (is)
CA (1)	CA2290973C (is)
CO (1)	CO4940405A1 (is)
DE (1)	DE69820608T2 (is)
DK (1)	DK0980241T3 (is)
DZ (1)	DZ2544A1 (is)
EA (1)	EA001905B1 (is)
ES (1)	ES2210760T3 (is)
GT (1)	GT199800090A (is)
HR (1)	HRP980378B1 (is)
HU (1)	HUP0002250A3 (is)
ID (1)	ID24673A (is)
IL (1)	IL133075A0 (is)
IS (1)	IS5266A (is)
MA (1)	MA24586A1 (is)
MY (1)	MY119728A (is)
NO (1)	NO996492L (is)
NZ (1)	NZ501252A (is)
OA (1)	OA11246A (is)
PA (1)	PA8454001A1 (is)
PE (1)	PE97299A1 (is)
PL (1)	PL337807A1 (is)
PT (1)	PT980241E (is)
SK (1)	SK282914B6 (is)
TN (1)	TNSN98123A1 (is)
TR (1)	TR199903282T2 (is)
TW (1)	TW382597B (is)
UA (1)	UA68350C2 (is)
UY (1)	UY25070A1 (is)
WO (1)	WO1999001113A1 (is)
ZA (1)	ZA985709B (is)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727283B2 (en)	1998-10-13	2004-04-27	Pfizer Inc.	Sertraline oral concentrate
WO2000021521A2 (en) *	1998-10-13	2000-04-20	Pfizer Products Inc.	Sertraline oral concentrate
PL211402B1 (pl)	1999-09-03	2012-05-31	Apbi Holdings	Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
MXPA03001771A (es)	2000-08-30	2003-06-04	Pfizer Prod Inc	Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
EP1375659A1 (en) *	2002-06-18	2004-01-02	Laboratorio di Diagnostica Moleculare	Soluble capsules containing stock mixtures for easy preparation of chemical or biological solutions
EP1556000A1 (en) *	2002-10-31	2005-07-27	Alza Corporation	Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs
WO2016020936A2 (en) *	2014-07-21	2016-02-11	Patel Jayendrakumar Dasharathlal	A novel oral gastroretentive pharmaceutical dosage form
CN108014087A (zh) *	2017-12-27	2018-05-11	江苏联环药业股份有限公司	一种盐酸舍曲林胶囊的制备方法
GB2630572A (en)	2023-05-29	2024-12-04	Novumgen Ltd	An orally disintegrating tablet of sertraline and its process of preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996009047A1 (en) *	1994-09-19	1996-03-28	The Du Pont Merck Pharmaceutical Company	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
EP0768083A2 (en) *	1995-07-17	1997-04-16	Pfizer Inc.	The use of sertraline to treat post myocardial infarction patients

1998
- 1998-06-16 BR BR9809712-1A patent/BR9809712A/pt not_active Application Discontinuation
- 1998-06-16 ID IDW991697A patent/ID24673A/id unknown
- 1998-06-16 CA CA002290973A patent/CA2290973C/en not_active Expired - Fee Related
- 1998-06-16 AU AU75450/98A patent/AU724635B2/en not_active Ceased
- 1998-06-16 HU HU0002250A patent/HUP0002250A3/hu unknown
- 1998-06-16 SK SK1805-99A patent/SK282914B6/sk unknown
- 1998-06-16 DE DE69820608T patent/DE69820608T2/de not_active Expired - Fee Related
- 1998-06-16 TR TR1999/03282T patent/TR199903282T2/xx unknown
- 1998-06-16 EA EA199900963A patent/EA001905B1/ru not_active IP Right Cessation
- 1998-06-16 KR KR10-1999-7011596A patent/KR100371730B1/ko not_active Expired - Fee Related
- 1998-06-16 IL IL13307598A patent/IL133075A0/xx unknown
- 1998-06-16 NZ NZ501252A patent/NZ501252A/en unknown
- 1998-06-16 DK DK98923021T patent/DK0980241T3/da active
- 1998-06-16 PT PT98923021T patent/PT980241E/pt unknown
- 1998-06-16 ES ES98923021T patent/ES2210760T3/es not_active Expired - Lifetime
- 1998-06-16 JP JP50677699A patent/JP3585245B2/ja not_active Expired - Fee Related
- 1998-06-16 PL PL98337807A patent/PL337807A1/xx unknown
- 1998-06-16 UA UA99116393A patent/UA68350C2/uk unknown
- 1998-06-16 EP EP98923021A patent/EP0980241B1/en not_active Expired - Lifetime
- 1998-06-16 CN CN98806765A patent/CN1261792A/zh active Pending
- 1998-06-16 WO PCT/IB1998/000936 patent/WO1999001113A1/en not_active Ceased
- 1998-06-16 AT AT98923021T patent/ATE256457T1/de not_active IP Right Cessation
- 1998-06-19 PA PA19988454001A patent/PA8454001A1/es unknown
- 1998-06-25 AP APAP/P/1998/001279A patent/AP945A/en active
- 1998-06-25 TW TW087110254A patent/TW382597B/zh not_active IP Right Cessation
- 1998-06-26 PE PE1998000575A patent/PE97299A1/es not_active Application Discontinuation
- 1998-06-29 GT GT199800090A patent/GT199800090A/es unknown
- 1998-06-29 AR ARP980103145A patent/AR015916A1/es not_active Application Discontinuation
- 1998-06-29 MY MYPI98002949A patent/MY119728A/en unknown
- 1998-06-29 UY UY25070A patent/UY25070A1/es not_active IP Right Cessation
- 1998-06-30 DZ DZ980154A patent/DZ2544A1/xx active
- 1998-06-30 MA MA25145A patent/MA24586A1/fr unknown
- 1998-06-30 ZA ZA9805709A patent/ZA985709B/xx unknown
- 1998-06-30 TN TNTNSN98123A patent/TNSN98123A1/fr unknown
- 1998-07-01 CO CO98037136A patent/CO4940405A1/es unknown
- 1998-07-01 HR HR980378A patent/HRP980378B1/xx not_active IP Right Cessation
1999
- 1999-11-23 IS IS5266A patent/IS5266A/is unknown
- 1999-11-23 BG BG103917A patent/BG103917A/bg unknown
- 1999-12-23 OA OA9900306A patent/OA11246A/en unknown
- 1999-12-27 NO NO996492A patent/NO996492L/no not_active Application Discontinuation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996009047A1 (en) *	1994-09-19	1996-03-28	The Du Pont Merck Pharmaceutical Company	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
EP0768083A2 (en) *	1995-07-17	1997-04-16	Pfizer Inc.	The use of sertraline to treat post myocardial infarction patients

Also Published As

Publication number	Publication date
EA001905B1 (ru)	2001-10-22
KR100371730B1 (ko)	2003-02-07
NO996492L (no)	2000-02-29
WO1999001113A1 (en)	1999-01-14
PL337807A1 (en)	2000-09-11
IS5266A (is)	1999-11-23
EA199900963A1 (ru)	2000-08-28
BR9809712A (pt)	2000-07-11
NO996492D0 (no)	1999-12-27
KR20010013588A (ko)	2001-02-26
SK180599A3 (en)	2001-01-18
CA2290973C (en)	2003-06-17
ES2210760T3 (es)	2004-07-01
EP0980241A1 (en)	2000-02-23
PT980241E (pt)	2004-03-31
HRP980378A2 (en)	1999-04-30
TR199903282T2 (xx)	2000-08-21
JP2000512316A (ja)	2000-09-19
PA8454001A1 (es)	2000-05-24
EP0980241B1 (en)	2003-12-17
OA11246A (en)	2002-11-19
CO4940405A1 (es)	2000-07-24
CA2290973A1 (en)	1999-01-14
AU724635B2 (en)	2000-09-28
TNSN98123A1 (fr)	2005-03-15
AP9801279A0 (en)	1998-06-30
NZ501252A (en)	2004-11-26
IL133075A0 (en)	2001-03-19
MA24586A1 (fr)	1998-12-31
ID24673A (id)	2000-07-27
SK282914B6 (sk)	2003-01-09
TW382597B (en)	2000-02-21
ZA985709B (en)	2000-01-10
ATE256457T1 (de)	2004-01-15
DZ2544A1 (fr)	2003-02-08
DK0980241T3 (da)	2004-04-05
AU7545098A (en)	1999-01-25
DE69820608T2 (de)	2004-12-23
HUP0002250A2 (hu)	2000-12-28
DE69820608D1 (de)	2004-01-29
HRP980378B1 (en)	2001-12-31
MY119728A (en)	2005-07-29
PE97299A1 (es)	1999-10-13
UY25070A1 (es)	2000-12-29
UA68350C2 (en)	2004-08-16
JP3585245B2 (ja)	2004-11-04
GT199800090A (es)	1999-12-21
HUP0002250A3 (en)	2001-01-29
CN1261792A (zh)	2000-08-02
BG103917A (bg)	2000-07-31
AR015916A1 (es)	2001-05-30

Publication	Publication Date	Title
US7115565B2 (en)	2006-10-03	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US5391377A (en)	1995-02-21	Biphasic release formations for lipophilic acids
RU2211047C2 (ru)	2003-08-27	Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
ES2326783T3 (es)	2009-10-20	Composiciones de n-benzoilestaurosporina espontaneamente dispersables.
JP2002531515A (ja)	2002-09-24	水に難溶性の薬剤のための自己乳化組成物
AU724635B2 (en)	2000-09-28	Gelatine encapsulated solution dosage forms of sertraline
JP2004520398A (ja)	2004-07-08	経口生物学的利用能が改善されたパクリタキセルの化学療法マイクロエマルジョン組成物
JPH0840936A (ja)	1996-02-13	経口投与薬物のための製剤
US20030133974A1 (en)	2003-07-17	Encapsulated solution dosage forms of sertraline
US4699776A (en)	1987-10-13	Suppositories containing analgesics, antipyretics or anti-inflammatory agents
STRICKLEY et al.	2007	Solubilizing vehicles for oral formulation development
MXPA99012099A (en)	2000-09-04	Gelatine encapsulated solution dosage forms of sertraline
CZ464299A3 (cs)	2000-04-12	Želatinové zapouzdření roztokové dávkovači formy sertralinu
HK1028882A (en)	2001-03-09	Gelatine encapsulated solution dosage forms of sertraline
AU2922800A (en)	2000-09-21	Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
TW200922637A (en)	2009-06-01	Pharmaceutical composition with enhanced bioavailability
AU2002249926A1 (en)	2002-08-28	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability